Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 344 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Arthritis Multiple Joint Clear all
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT01264770
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07280156
View directory record Official record
Conditions
Gout
Interventions
PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate
Biological · Drug · Other
Lead sponsor
Protalix
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Little Rock, Arkansas • El Cajon, California • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee

NCT02326961
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celution Device, Placebo
Device · Other
Lead sponsor
Cytori Therapeutics
Industry
Eligibility
40 Years to 69 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Mesa, Arizona • Little Rock, Arkansas • La Mesa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Long Term Open Label Continuation Study

NCT00195650
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
74
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Not applicable Interventional

Shared Decision Making and How It Impacts the Patient Understanding

NCT04011488
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Shared Decision Making Tool
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
45 Years to 64 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Not applicable Interventional Results available

Tritanium® Primary Acetabular Shell Study

NCT01063751
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Tritanium® Primary Acetabular Shell
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
7
States / cities
St. Helena, California • Tampa, Florida • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

NCT00882024
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
Tranilast, Placebo
Drug
Lead sponsor
Nuon Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2011 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Phase 3 Interventional

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib, Active Comparator, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Withdrawn Not applicable Interventional

Restoration Anatomic Acetabular Shell Revision Study

NCT05591859
View directory record Official record
Conditions
Arthropathy, Hip Arthropathy, Hip Osteoarthritis
Interventions
Restoration Anatomic Acetabular Shell
Device
Lead sponsor
Stryker Orthopaedics
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642
View directory record Official record
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.

NCT05796908
View directory record Official record
Conditions
Arthritis, Unstable Radial Head, Proximal Radioulnar Joint Instability, Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
Interventions
Aptis PRUJ Prosthesis
Device
Lead sponsor
Aptis Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
7
States / cities
Carmel, Indiana • Louisville, Kentucky • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Missed Dose Study

NCT00533897
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
13
States / cities
Los Angeles, California • Trumbull, Connecticut • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

NCT01636817
View directory record Official record
Conditions
Inflammation, Rheumatoid Arthritis
Interventions
NNC0109-0012, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
92
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Not applicable Interventional

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

NCT04238143
View directory record Official record
Conditions
Osteoarthritis, Osteo Arthritis Knee, Osteo Arthritis Shoulders, Osteoarthritis of Multiple Joints, Osteoarthritis, Hip, Osteoarthritis - Ankle/Foot
Interventions
Tissue Stromal Vascular Fraction (tSVF) Arm 1, PRP Concentrate Arm 1, Tissue Stromal Vascular Fraction (tSVF) Arm 2, PRP Concentrate Arm 2, Cellular Stromal Vascular Fraction (cSVF) Arm 2, Cellular Stromal Vascular Fraction (cSVF) Arm 3, Sterile Normal Saline (IV Solution)
Procedure · Biological · Drug
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Valencia, California • Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting No phase listed Observational

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728
View directory record Official record
Conditions
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Interventions
Not listed
Lead sponsor
Exactech
Industry
Eligibility
21 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2031
U.S. locations
24
States / cities
Laguna Woods, California • Redwood City, California • Stockton, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Global® AP™ Total Shoulder Arthroplasty

NCT00719771
View directory record Official record
Conditions
Osteoarthritis
Interventions
Global® AP™ Total shoulder arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Phoenix, Arizona • Asheville, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study in Japanese Subjects

NCT01872832
View directory record Official record
Conditions
Gout
Interventions
RDEA3170 and Placebo
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis

NCT01749787
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
PRTX-100 at 1.5 mcg/kg, PRTX-100 at 3.0 mcg/kg, PRTX-100 at 6.0 mcg/kg, PRTX-100 at 12.0 mcg/kg, PRTX-100 at 240 mcg, Placebo, PRTX-100 at 420 mcg
Drug
Lead sponsor
Protalex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Study Utilizing Rilonacept in Gout Exacerbations

NCT00855920
View directory record Official record
Conditions
Acute Gout Flare
Interventions
Rilonacept, Indomethacin, Placebo (for Indomethacin), Placebo (for Rilonacept)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional

Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

NCT00928317
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ART621, Placebo
Drug
Lead sponsor
Arana Therapeutics Ltd
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Tampa, Florida • Springfield, Illinois • Lincoln, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2010 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

NCT01925261
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
TPX-100 50mg, TPX-100 100mg, TPX-100 200mg, TPX-100 20mg, Placebo
Drug
Lead sponsor
OrthoTrophix, Inc
Industry
Eligibility
25 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of NMES Therapy for Pain Relief Associated With Knee Osteoarthritis

NCT04367597
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Home-based Neuromuscular Electrical Stimulation (NMES) therapy
Device
Lead sponsor
CyMedica Orthopedics, Inc
Industry
Eligibility
21 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
5
States / cities
Tucson, Arizona • Houston, Texas • Katy, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

NCT00048568
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2011 · Synced Jul 22, 2026, 12:02 PM EDT